Search results for " infectious disease"

showing 7 items of 167 documents

A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculos…

2016

Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis…

medicine.medical_specialtyCancer ResearchComplicationsSettore MED/17 - Malattie InfettiveEpidemiologyBladder030232 urology & nephrologyUrologyShort ReportInfectious DiseaseGastroenterologySepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicineGranulomatous prostatitisBladder; Calmette; Complications; Guérin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer ResearchPneumonitisHepatitisLatent tuberculosisbusiness.industryIntravesicalIsoniazidmedicine.diseaseInfectious DiseasesOncology030220 oncology & carcinogenesisOrchitisSuperficial Bladder CarcinomabusinessComplicationGuérinmedicine.drugCalmetteInfectious Agents and Cancer
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

2011

Abstract The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection fro…

medicine.medical_specialtyEndotheliummedicine.medical_treatmentlcsh:MedicineInflammationReviewAscorbic AcidMicrobiologyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySepsisNeoplasmsSepsisInternal medicinemedicineHumansEndotheliumAscorbic Acid DeficiencyCancerImmunology and Infectious DiseaseMedicine(all)Biochemistry Genetics and Molecular Biology(all)business.industrylcsh:RImmunityCancerGeneral Medicinemedicine.diseaseAscorbic acidSystemic inflammatory response syndromemedicine.anatomical_structureOncologyInjections IntravenousImmunologyAscorbic Acid DeficiencyIntravenous ascorbic acidmedicine.symptombusinessAdjuvantJournal of Translational Medicine
researchProduct

Community acquired pneumonia in children: Outpatient treatment and prevention

2015

There have been significant changes in community acquired pneumonia (CAP) in children in the last decade. These changes are related to epidemiology and clinical presentation. Resistance to antibiotics is also a changing issue. These all have to be considered when treating Community acquired pneumonia (CAP). In this document, two of the main Spanish pediatric societies involved in the treatment of CAP in children, propose a consensus concerning therapeutic approach. These societies are the Spanish Society of Paediatric Infectious Diseases and the Spanish Society of Paediatric Chest Diseases. The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) has also been …

medicine.medical_specialtybusiness.industryNeumonía adquirida en la comunidadmedia_common.quotation_subjectAdvisory committeeResistenciasResistance (psychoanalysis)medicine.diseasePediatricsRJ1-570Paediatric infectious diseasesTherapeutic approachPresentationPrevenciónStreptococcus pneumoniaeCommunity-acquired pneumoniaManagement of Technology and InnovationEpidemiologyTratamientoMedicinebusinessIntensive care medicineNiñosmedia_commonAnales de Pediatría (English Edition)
researchProduct

COVID-19 Deaths: Are We Sure It Is Pneumonia? Please, Autopsy, Autopsy, Autopsy!

2020

The current outbreak of COVID-19 severe respiratory disease, which started in Wuhan, China, is an ongoing challenge, and a major threat to public health that requires surveillance, prompt diagnosis, and research efforts to understand this emergent pathogen and to develop an effective response. Due to the scientific community’s efforts, there is an increasing body of published studies describing the virus’ biology, its transmission and diagnosis, its clinical features, its radiological findings, and the development of candidate therapeutics and vaccines. Despite the decline in postmortem examination rate, autopsy remains the gold standard to determine why and how death ha…

medicine.medical_specialtydiagnosisCOVID-19 ; autopsy ; infectious diseases ; diagnosisinfectious diseaselcsh:MedicineAutopsyDiseaseinfectious diseases03 medical and health sciences0302 clinical medicineautopsymedicineSampling (medicine)030216 legal & forensic medicineIntensive care medicinePostmortem Diagnosisbusiness.industryTransmission (medicine)Public healthGold standardlcsh:RCOVID-19General Medicinemedicine.diseasePneumoniaEditorial030220 oncology & carcinogenesisbusinessJournal of Clinical Medicine
researchProduct

Double copies of blaKPC-3::Tn4401a on an IncX3 plasmid in Klebsiella pneumoniae successful clone ST512 from Italy

2015

ABSTRACT A carbapenem-resistant sequence type 512 (ST512) Klebsiella pneumoniae carbapenemase 3 (KPC-3)-producing K. pneumoniae strain showing a novel variant plasmid content was isolated in Palermo, Italy, in 2014. ST512 is a worldwide successful clone associated with the spread of bla KPC genes located on the IncFIIk pKpQIL plasmid. In our ST512 strain, the bla KPC-3 gene was unusually located on an IncX3 plasmid, whose complete sequence was determined. Two copies of bla KPC-3 ::Tn 4401a caused by intramolecular transposition events were detected in the plasmid.

transposonsequence analysispolymerase chain reactionDrug ResistanceGene DosageSettore MED/42 - Igiene Generale E Applicatabacterial proteinbeta-Lactamaseopen reading framecarbapenemasePlasmidminocyclineplasmid DNAmeropenemPharmacology (medical)geneticscolistincefpodoximeceftazidime610 Medicine & healthCarbapenemBacterialpolymyxin Btimentingene expression regulationbacteriumKlebsiella pneumoniae carbapenemase 3 producing Klebsiella pneumoniae3. Good healthantiinfective agentmicrobial sensitivity testKlebsiella pneumoniaeItalypriority journaltigecyclineMultipleclone (Java method)cefotaxime030106 microbiologyKlebsiella pneumoniae carbapenemase 3tobramycinMicrobial Sensitivity Testsgentamicinpiperacillin plus tazobactamchemistryGene dosageArticleMicrobiology03 medical and health sciencesComplete sequenceClone CellOpen Reading FramesertapenemBacterial Proteinsmultidrug resistanceextensively drug resistant bacteriumAnti-Bacterial AgentcefepimePharmacologylevofloxacinmicrobiologycefoxitinbiochemical phenomena metabolism and nutritionbacterial infections and mycosesVirologyAnti-Bacterial Agents; Bacterial Proteins; Carbapenems; Clone Cells; Drug Resistance Multiple Bacterial; Gene Dosage; Italy; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Open Reading Frames; Plasmids; beta-Lactamases; DNA Transposable Elements; Gene Expression Regulation Bacterial; Pharmacology (medical); Pharmacology; Infectious Diseasesantibiotic sensitivityClone CellsKlebsiella InfectionsceftriaxoneCarbapenemsbacterial genetics0301 basic medicinemolecular cloningSettore MED/07 - Microbiologia E Microbiologia ClinicaKlebsiella pneumoniaeTransposition (music)Drug Resistance Multiple Bacterialpolycyclic compoundsgenetic screeningcell clonecarbapenem derivativeKlebsiella infectionunclassified drugAnti-Bacterial AgentsInfectious Diseasesbacterial genePlasmidsenzymologydoripenemBiologyminimum inhibitory concentrationbeta-Lactamasesbeta lactamaseMechanisms of ResistanceciprofloxacinAmikacin; aztreonam; carbapenemase; cefepime; cefotaxime; cefoxitin; cefpodoxime; ceftazidime; ceftriaxone; ciprofloxacin; colistin; cotrimoxazole; doripenem; doxycycline; ertapenem; gentamicin; imipenem; Klebsiella pneumoniae carbapenemase 3; levofloxacin; meropenem; minocycline; piperacillin plus tazobactam; plasmid DNA; polymyxin B; tigecycline; timentin; tobramycin; unclassified drug; antiinfective agent; bacterial protein; beta lactamase; carbapenem derivative; transposon antibiotic sensitivity; Article; bacterial gene; bacterial genetics; bacterial strain; bacterium; bacterium detection; bacterium isolation; Escherichia coli; extensively drug resistant bacterium; gene dosage; genetic screening; Italy; Klebsiella pneumoniae; Klebsiella pneumoniae carbapenemase 3 producing Klebsiella pneumoniae; minimum inhibitory concentration; molecular cloning; nonhuman; polymerase chain reaction; priority journal; sequence analysis; cell clone; chemistry; drug effects; enzymology; gene expression regulation; genetics; isolation and purification; Klebsiella infection; Klebsiella pneumoniae; metabolism; microbial sensitivity test; microbiology; multidrug resistance; open reading frame; plasmid; transposon Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Clone Cells; DNA Transposable Elements; Drug Resistance Multiple Bacterial; Gene Dosage; Gene Expression Regulation Bacterial; Italy; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Open Reading Frames; Plasmidsplasmidbacterium isolationEscherichia coliGeneAmikacinbacterium detectionnonhumandoxycyclineisolation and purificationGene Expression Regulation Bacterialbiology.organism_classificationbacterial straincotrimoxazoleOpen reading frameDNA Transposable Elementdrug effectsDNA Transposable Elementsmetabolismaztreonamimipenem
researchProduct

Vacunas y evolución: ¿Por qué es importante entender la diversidad genética de los patógenos?

2013

Desde el punto de vista de las intervenciones en salud pública no hay mejor arma que aquella que permite prevenir la transmisión o aparición de la enfermedad. Dentro del campo de las enfermedades infecciosas las vacunas se han convertido en esa arma y han permitido controlar muchas de ellas. Hoy en día hay un gran número de enfermedades infecciosas emergentes para las que no existen vacunas o enfermedades olvidadas que están reemergiendo. Nuevas vacunas se están desarrollando para atacar a los patógenos que están relacionados con ellas. Sin embargo, y a pesar de la importancia del diseño de una buena vacuna, la diversidad genética de los patógenos no se ha tenido siempre en cuenta. El estud…

variación antigénicabiología; evoluciónvariació antigènica; tuberculosi; grip; sistema immune; malalties infecciosesevoluciónantigenic variationinfectious diseasesvariación antigénica; tuberculosis; gripe; sistema inmune; enfermedades infecciosassistema inmunebiologia; evolucióevolutionvariació antigènicagriptuberculosiantigenic variation; tuberculosis; flu; immune system; infectious diseasesbiology; evolutionflubiologygripemalalties infecciosesimmune systemtuberculosisevolucióenfermedades infecciosasbiologíasistema immunebiologia
researchProduct